Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...
As more drugs go subcutaneous, Phillips Medisize's Tony Bedford believes that high-dose biologics will become a prevalent ...
Most patients receiving a GLP-1 receptor agonist (RA) and a biologic continue co-therapy for over a year with few treatment-related adverse events.
Omalizumab or dupilumab suggested for adults with moderate-to-severe allergic asthma, history of exacerbations requiring oral corticosteroids ...
Medicare coverage for biologic therapies -- a mainstay of treatment for rheumatoid arthritis-- has been in flux recently. Medicare Part B coverage for biologic therapy ended in 2004, and the Medicare ...
Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...
Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and ...
It is the first clinical trial to evaluate a biologic therapy to prevent serious adverse outcomes in pregnant women with APS and their babies. The study results were published online on April 10, 2025 ...
Please provide your email address to receive an email when new articles are posted on . Less than 15% of PCPs reported managing patients with uncontrolled asthma at least once a week. More PCPs ...
Biologic Therapies has announced it has received FDA clearance for its new bone marrow aspiration catheter, according to a news release. The Bio-MAC bone marrow aspiration catheter is designed to ...
The American College of Chest Physicians ® (CHEST) recently released a new clinical guideline on biologic management in ...